Health
Antibody improves progression-free survival in patients with advanced prostate cancer – News-Medical.Net
An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasised, castration-resistant prostate cancer.
Reviewed by Emily Henderson, B.Sc.Sep 29 2020
An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasized, castration-resistant prostate cancer.
This is the finding of the long-term analyses of an international phase 3 clinical trial, recently published in the leading journal “European Urology”. The study showed that overall survival was 2 – 3 times higher than in the placebo arm.
Ipilimumab is a humanized monoclonal IgG1 antibody that is…
-
General13 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
Noosa News20 hours agoPerth Royal Show vendors upset by price hikes, say crowds are down in 2025
-
Business21 hours agoBell Potter names the best ASX shares to buy in October
-
General19 hours agoAustralia welcomes Gaza peace progress, hostage release